{"altmetric_id":4684444,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["Ascend Biopharmaceuticals Ltd"],"first_seen_on":"2015-10-28T11:29:21+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1483698165,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02550678?term=ascend+asn-002&rank=2","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02550678?term=ascend+asn-002&amp;rank=2","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02550678?term=asn-002&ran"],"nct_id":"NCT02550678","pubdate":"2015-09-10T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001)","type":"clinical_trial_study_record"},"altmetric_score":{"score":10.25,"score_history":{"1y":0.25,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":10.25},"context_for_score":{"all":{"total_number_of_other_articles":7992937,"mean":6.7399601605663,"rank":762315,"this_scored_higher_than_pct":90,"this_scored_higher_than":7223459,"rank_type":"exact","sample_size":7992937,"percentile":90},"similar_age_3m":{"total_number_of_other_articles":242572,"mean":9.6476942998132,"rank":33135,"this_scored_higher_than_pct":86,"this_scored_higher_than":209037,"rank_type":"exact","sample_size":242572,"percentile":86},"this_journal":{"total_number_of_other_articles":22193,"mean":10.368782894737,"rank":2608,"this_scored_higher_than_pct":88,"this_scored_higher_than":19555,"rank_type":"exact","sample_size":22193,"percentile":88},"similar_age_this_journal_3m":{"total_number_of_other_articles":1066,"mean":14.377092957746,"rank":154,"this_scored_higher_than_pct":85,"this_scored_higher_than":908,"rank_type":"exact","sample_size":1066,"percentile":85}}},"demographics":[],"counts":{"total":{"posts_count":2},"news":{"unique_users_count":1,"unique_users":["reuters"],"posts_count":1},"facebook":{"unique_users_count":1,"unique_users":["160893710733319"],"posts_count":1}},"posts":{"news":[{"title":"Ascend Announces Patients with Nodular Basal Cell Carcinoma Receives First Dose of ASN-002 in Phase 1\/2a Study","url":"http:\/\/ct.moreover.com\/?a=22937647689&p=1pl&v=1&x=a9hR27PQ_JO-pfyCXsesFA","license":"public","citation_ids":[4684444],"posted_on":"2015-10-07T13:14:20+00:00","summary":"MELBOURNE, Australia, Oct. 7, 2015 \/PRNewswire\/ -- Ascend Biopharmaceuticals, a Melbourne-based immunotherapy company focused on developing innovative cancer therapeutics, today announced the first nodular Basal Cell Carcinoma patient (nBCC) dosed\u2026","author":{"name":"Reuters","url":"http:\/\/www.reuters.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/008\/normal\/reuters.png?1369846897"}}],"facebook":[{"title":"Anna","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=749763111846373&id=160893710733319","license":"public","citation_ids":[4684444],"posted_on":"2017-01-06T10:22:45+00:00","summary":"May 2017 be a good one for each of you and may you be surrounded by loving family and friends as you face the challenges which Gorlin Syndrome presents to us.\nI have received good news this week: Ascend Biopharmaceuticals Ltd are ready to start a trial of","author":{"name":"Sindrome di Gorlin Italia","url":"https:\/\/www.facebook.com\/160893710733319","facebook_wall_name":"Sindrome di Gorlin Italia","image":"https:\/\/graph.facebook.com\/160893710733319\/picture","id_on_source":"160893710733319"}}]}}